BiotechTube

AAVLP-HPV + Placebo

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Papillomavirus Infections

Conditions

Papillomavirus Infections

Trial Timeline

Feb 28, 2019 → May 29, 2020

NCT ID
NCT03929172

About AAVLP-HPV + Placebo

AAVLP-HPV + Placebo is a phase 1 stage product being developed by 2A Pharma for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03929172. Target conditions include Papillomavirus Infections.

What happened to similar drugs?

4 of 20 similar drugs in Papillomavirus Infections were approved

Approved (4) Terminated (0) Active (16)
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅GardasilMerckApproved
✅Gardasil-9MerckApproved
✅Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
🔄9vHPV vaccineMerckPhase 3
🔄V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
🔄V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03929172Phase 1Completed

Competing Products

20 competing products in Papillomavirus Infections

See all competitors
ProductCompanyStageHype Score
9vHPV vaccineMerckPhase 3
44
Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
43
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
40
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
40
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administrationMerckPre-clinical
26
GardasilMerckApproved
43
GardasilMerckPhase 2
35
9vHPV VaccineMerckPhase 3
44
9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3
40
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant VaccineMerckPhase 3
40
V503 + GARDASILMerckPhase 3
40
9vHPV VaccineMerckPhase 3
44
Gardasil vaccineMerckPre-clinical
26
V503MerckPhase 3
40
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) + PlaceboMerckPhase 3
40
V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)MerckPhase 3
40
9vHPV vaccineMerckPhase 3
40
Gardasil™ + PlaceboMerckPhase 3
40
V503 + GardasilMerckPhase 3
44
9vHPV vaccineMerckPhase 3
40